Navigation Links
Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
Date:5/29/2008

HOPKINTON, Mass., May 29 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that the Company will hold its Annual Meeting of Stockholders Thursday, June 12, 2008 at 1:00 p.m. EDT at the offices of Wilmer Cutler Pickering Hale & Dorr, 60 State Street, Boston, MA.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease. The Company has research collaborations with Harvard Medical School and Children's Hospital Boston.

Alseres is a trademark and Cethrin and Al
'/>"/>

SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Vista Partners Initiates Coverage on Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE)
2. Alseres Pharmaceuticals, Inc. Reports First Quarter 2008 Operational and Financial Results
3. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
4. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
5. Alseres Pharmaceuticals, Inc. Complies With NASDAQ Rule Regarding Recently Filed 10-K
6. Alseres Pharmaceuticals, Inc. Raises $5 Million
7. Alseres Pharmaceuticals, Inc. to Present at New York Society of Security Analysts Conference
8. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss First Quarter 2008 Results
9. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
10. Aida Pharmaceuticals, Inc. Announces Availability of Downloadable Corporate Synopsis on its Website
11. Lotus Pharmaceuticals, Inc. Announces Fourth Quarter and Fiscal Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...PHIA, Nov. 21 NursingCenter.com, t...cation and peer reviewed content, has been,update...0,000 registered,users. Powered by Lippincott Wil...provides over 900 peer-reviewed continuing educati...from more than 50 leading nursing journals.,Lippi...
(Date:11/21/2008)..., Nov. 21 The general membership o...nduct three new individuals at their Annual,Award...e hotel in New York. A,Lifetime Achievement Award...nto the Medical Advertising Hall of Fame are: , ... with an account position,at Sudler & Henness...
(Date:11/21/2008)...und 2 popular drugs do not cause genetic damage th...21 (HealthDay News) -- Two popular medications for... (ADHD) do not cause genetic damage linked to an i...ays. , The study, done by researchers at Duke U...es of Health, counters a previous one that reporte...
(Date:11/21/2008)...Nov. 21 In a statewide survey, 33 ...nstitute for Surgery at Presbyterian Hospital of D...annual listing of " Super Doctors ." , , Ea...th Key Professional Media, Inc. to survey more tha... Texas to ask, "If you needed medical care, which ...
Breaking Medicine News(10 mins):Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 2Health News:Ronald Pantello, Harry Sweeney, and David Wood Voted Into Medical Advertising Hall of Fame. 3Health News:ADHD Medications Don't Pose Cancer Risk 2Health News:Annual List of 'Super Doctors' Features 33 Texas Institute for Surgery Physicians 2
...e fixed on Boeing here Sunday when the US aircraft...ssenger jet it hopes will revolutionize air travel...engers and is capable of flying long-haul routes u...e pumping out fewer greenhouse gases, will be roll...
...ciers are receding and lakes are drying up in Lati...en while some sections are adamantly skeptical abo...rted the disappearance of a whole lake in the sout...lake, some 20,000 square metres in area, in the Be...
... is also draconian. Any presumed violation of the ...commercial fishing pond in Pasir Ris Drive 6, will...eding mosquitoes. The area is dubbed the number on...the nation, reporting close to 40 new cases as of ...
...ljana in Slovenia have solved the mystery behind w...fore their eyes. Samo and Marko Kreft of the u...d oil, say that it happens due to the unique makeu...specific physical properties of substances themsel...
Other Medicine News:Health News:Boeing Unveils 'green' Dreamliner Passenger Jet 2Health News:Chilean Lake Disappears, Thanks to Global Warming 2Health News:Dengue Surge in Singapore, Man Prosecuted for Breeding Mosquitoes 2
(Date:11/20/2008)...- The Scandinavian-based drug,development company...on its,lead antimicrobial candidate LTX-109. Pres...wed that the novel lytic peptidomimetic has an ult...er towards killing Staphylococcus,aureus and Stre...gs. In,addition to this it has proven effective a...
(Date:11/19/2008)...significance , , ISELIN, N.J., Nov. 19 /PR...: PARS ) today announced results from its Phase ... drug delivery technology formulated with 3% Diclo... randomized, double-blinded, placebo-controlled st...ny,s 3% Diclofenac Diethanolamine NanoEmulsion cre...
(Date:11/19/2008)...a contract development and,manufacturing organiza...t,phase launch of its contract facility in Delawa...e process, facility and capacity problems commonly...w-volume clinical and,early-stage commercial ster... invest over $100 million and four years to develo...
(Date:11/18/2008)...make a donation or send a Christmas Seals e-card ,...re/ -- Millions will receive Christmas Seals in th...ssociation. These decorative holiday stamps are pa...to 1907 when the Lung Association led efforts to c...alive today have no vivid memories of how widespre...
Breaking Medicine Technology:Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Isogen Launches Major New Facility to Address Global Biopharma Demand 2American Lung Association Celebrates 101st Annual Christmas Seals Campaign 2Julia Zeitlinger named Pew Scholar 3651 1Julia Zeitlinger named Pew Scholar 3651 2INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 1INACSL and Elsevier partner to publish Clinical Simulation in Nursing 21981 2AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 1AHIP Statement on American Medical Association 28AMA 29 Claims Processing Report 21978 2Mylan Announces Tentative FDA Approval for Generic Version of Antihypertensive Avalide 28R 29 Tablets 21975 1
...ngress of European Hematology,Association (EHA) -,...all/ --,Immunomedics, Inc. , a biopharmaceutical c... to treat cancer and other serious,diseases, today...s,of EHA in Vienna, Austria, showed positive respo... treated with a new,radioimmunotherapy (RAIT) usin...
...ational Reserve" May Also Affect,Alzheimer,s Risk ...e/ -- A new study,suggests that treating risk fact...od pressure and diabetes, may slow the progression...orted today at the,2nd Alzheimer,s Association Int... Washington, DC. , Two new studies presented at th...
Other Medicine Technology:Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 2Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 3Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 4Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 5Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 6Treating Heart Disease Risk Factors May Slow Alzheimer's Disease,Progression 7
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
...tories is a national reference laboratory and a wo...nd development. ARUP offers an extensive test menu...nical and anatomic pathology. Owned by the Univers...re than half of the nation's university teaching h...
Medicine Products: